Holen Sie sich die Stockscreener-App
1.10
2.80%
0.03
Handel nachbörslich:
1.10
Pliant Therapeutics Inc Aktie (PLRX) Neueste Nachrichten
Pliant Therapeutics (PLRX) Advances Clinical Program Amidst Chal - GuruFocus
Monaco Asset Management SAM Purchases Shares of 1,938,747 Pliant Therapeutics, Inc. $PLRX - MarketBeat
Pliant Therapeutics Inc (FRA:9PT) Stock Price, Trades & News - GuruFocus
Pliant Therapeutics (NASDAQ:PLRX) Downgraded by Wall Street Zen to Sell - MarketBeat
Pliant Therapeutics (PLRX) gains 8.9% institutional holder in ADAR1 Capital - Stock Titan
Pliant Therapeutics (PLRX): Citadel entities, Kenneth Griffin report 3.5% holding - Stock Titan
Price performance - Yahoo Finance Australia
CCORF Maintains Pliant Therapeutics(PLRX.US) With Hold Rating, Maintains Target Price $3 - Moomoo
PLRX (Pliant Therapeutics) 12-1 Month Momentum % : -34.12% (As of Aug. 12, 2026) - GuruFocus
Pliant Therapeutics cuts Q2 loss to $22.4M on lower costs - scanx.trade
Form 8K Pliant Therapeutics Inc For: 11 August By Investing.com - Investing.com Nigeria
Pliant Therapeutics (NASDAQ:PLRX) Posts Earnings Results, Misses Estimates By $0.02 EPS - MarketBeat
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results - The Manila Times
Pliant Therapeutics (PLRX) halves quarterly loss and reports $159.6M in cash reserves - Stock Titan
BRIEF-Pliant Therapeutics Q2 Net Income USD -22.371 Million - TradingView
Pliant Therapeutics Inc (PLRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Pliant Therapeutics Inc (PLRX) Stock News Today - TradingKey
Pliant Therapeutics, Inc. expected to post a loss of 34 cents a shareEarnings Preview - TradingView
Pliant Therapeutics (PLRX) Expected to Release Quarterly Earnings on Thursday - MarketBeat
Pliant Therapeutics (PLRX) Holds Near Support Amid Modest DeclineFibonacci Extension - dars.gov.et
Pliant Therapeutics (PLRX) Edges Higher Amid Tight Trading Range — Key Levels in FocusStandard Deviation - dars.gov.et
Pliant Therapeutics Inc (PLRX) Income Statement - TradingKey
Pliant Therapeutics Inc (PLRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Pliant Therapeutics Inc (PLRX) Cash Flow - TradingKey
Pliant Therapeutics Inc (PLRX) Balance Sheet - TradingKey
Pliant Therapeutics Inc (PLRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Pliant Therapeutics Inc (PLRX) Institutional Confidence - TradingKey
Pliant Therapeutics Inc (PLRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
PLRX|Pliant Therapeutics Inc|Price:1.080|Chg%:-0.010 - TradingKey
PLRX|Pliant Therapeutics Inc|Price:1.090|Chg%:+0.010 - TradingKey
Pliant Therapeutics Inc (PLRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Rating of "Reduce" by Brokerages - MarketBeat
Pliant Therapeutics (NASDAQ:PLRX) Trading Down 7%Here's Why - MarketBeat
Pliant enters U.S. market via Coastal partnership to expand B2B payments - scanx.trade
Pliant Therapeutics, Inc. Files Form 8-K with SEC Detailing Company Information and NASDAQ Listing - Minichart
Form 4 Pliant Therapeutics Inc For: 13 July By Investing.com - Investing.com Nigeria
Pliant Therapeutics adds independent directors to strengthen R&D - TipRanks
Pliant Therapeutics (PLRX) director Robert Iannone submits initial Form 3 - Stock Titan
Pliant Therapeutics (PLRX) director files initial insider ownership statement - Stock Titan
Pliant Therapeutics (PLRX) awards 60,000 stock options to director Flavia Borellini - Stock Titan
[8-K] PLIANT THERAPEUTICS, INC. Reports Material Event - Stock Titan
Pliant Therapeutics adds two directors with oncology expertise - Investing.com UK
Pliant Therapeutics appoints Flavia Borellini to board, strengthening executive leadership - Traders Union
Pliant Therapeutics adds two directors with oncology expertise By Investing.com - Investing.com Nigeria
Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of Directors - The Manila Times
Pliant Therapeutics appoints Flavia Borellini and Robert Iannone to Board - scanx.trade
Price to sales forward of Pliant Therapeutics, Inc. – NASDAQ:PLRX - TradingView
Price to earnings forward of Pliant Therapeutics, Inc. – FWB:9PT - TradingView
Price to book forward of Pliant Therapeutics, Inc. – NASDAQ:PLRX - TradingView
Enterprise value to revenue forward of Pliant Therapeutics, Inc. – FWB:9PT - TradingView
Enterprise value to revenue forward of Pliant Therapeutics, Inc. – NASDAQ:PLRX - TradingView
Price to earnings forward of Pliant Therapeutics, Inc. – TRADEGATE:9PT - TradingView
Pliant Therapeutics (PLRX) Stock Edges Lower, Holds Closely Above Key SupportAccumulation Line - dars.gov.et
Pliant Therapeutics (PLRX) Holds Steady at $1.17 as Traders Eye Key Support and Resistance LevelsVolume Dry Up - dars.gov.et
Enterprise value to EBITDA forward of Pliant Therapeutics, Inc. – NASDAQ:PLRX - TradingView
Enterprise value to EBITDA forward of Pliant Therapeutics, Inc. – GETTEX:9PT - TradingView
Pliant Therapeutics Inc. (PLRX) Q1 2026 Earnings: Narrower Loss Sends Stock HigherTech Earnings Analysis - dars.gov.et
Pliant Therapeutics (PLRX) Edges Higher Amid Consolidation Near SupportPre-Earnings Momentum - dars.gov.et
Pliant Therapeutics Inc. (PLRX) Q1 2026 Earnings: EPS Beat Highlights Cost DisciplineSegment Revenue Breakdown - dars.gov.et
PLRX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Pliant Therapeutics (PLRX) Inches Higher Amid Ongoing Volatility: Key Levels to WatchETF Inflow Streak - dars.gov.et
Pliant Therapeutics Inc (PLRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
9PT Forecast — Price Target — Prediction for 2027 - TradingView
1.80%
1.77%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):